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CC BY-NC-ND license (http://creativeBackground: Bloodstream infection is not uncommon in kidney transplant recipients (KTRs)
and is associated with mortality, graft loss, and increased medical expenses. Whether these
septic patients are more vulnerable to serious complications, resistant strains, or worse clin-
ical outcomes than other patient groups in the community-onset settings remains undeter-
mined.
Methods: A retrospective study was conducted at a medical center in southern Taiwan.
Community-onset bacteremia in the KTRs and a control population at the emergency depart-
ment were identified. Demographic data, clinical characteristics, bacteremic pathogens, anti-
microbial resistance, and clinical outcomes were recorded.
Results: Forty-one bacteremic episodes in the KTRs and 82 episodes in control patients were
studied. The KTR group had younger age, fewer malignancies, more urosepsis (61% vs. 22%,
p Z 0.004), and fewer biliary tract infections (0% vs. 13.4%, p Z 0.018). Escherichia coli
was the most commonly isolated pathogen in both the groups (51.2% and 41.5%, respectively).
No Klebsiella pneumoniae bacteremia was noted in the KTRs, compared with 14 (17.1%) epi-
sodes in the control group (p Z 0.010). Antimicrobial resistance profiles of bacteremic path-
ogens were similar (all p > 0.6). The KTRs with community-onset bacteremia did not have a
worse outcome (in-hospital mortality rate: 2.4% vs. 10%, p Z 0.172) nor more incompletet of Internal Medicine, National Cheng Kung University Hospital, Number 138, Sheng Li Road, 704,
mail.com (C.-C. Lee), winston3415@gmail.com (W.-C. Ko).
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686 C.-T. Cia et al.resolution of kidney injury after acute kidney injury events (21.1% vs. 25%, p > 0.99) than the
control group.
Conclusion: KTRs with community-onset bacteremia did not fare worse in terms of clinical
outcome and kidney injury.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Bloodstream infection is not uncommon in kidney trans-
plant recipients (KTRs) and could be lethal. The incidence
ranges from 0.7 to 11 episodes/100 patient-year.1,2 The
mortality rate of septicemia was 63% in the 1960s and
remained as high as 24.3% even in the 2000s.1e3 The graft
survival and medical expenses are also significantly
impacted by the sepsis episodes.4
Medical care for KTRs with sepsis is more difficult
because they are prone to kidney injury and drugedrug
interaction caused by their immunosuppressive agents such
as cyclosporin and tacrolimus. The condition is further
complicated by the pathogens with variable resistance to
cephalosporins and fluoroquinolones, as well as by a high
prevalence of extended-spectrum beta-lactamase (ESBL)-
producing strains among these patients.5e7
Also, the composition of patients visiting the emergency
department (ED) changed due to the advances in chemo-
therapies, antiretroviral therapies, and care for chronic
diseases. However, few reports compared the difference
between KTRs and other patient groups with bacteremia.
We conducted a retrospective study to assess the clinical
characteristics, pathogen distribution, and clinical
outcome of community-onset bacteremia among KTRs and
general population.Materials and methods
Study design and population
A retrospective study was conducted at a tertiary hospital
with approximately 1200 beds in southern Taiwan. All pa-
tients older than 18 years with International Classification
of Diseases-9 code V420 or kidney transplantation in the
discharge diagnosis and positive blood cultures collected at
the ED between 2005 and 2010 were included as the case
group. All bacteremia episodes were included except those
developing within 14 days after previous episodes with
identical pathogens. Those patients with graft failure and
regular hemodialysis were excluded as they often dis-
continued their immunosuppressants and had some type of
vascular access. In addition, we excluded all cases of
hospital-acquired bacteremic episodes.
For each bacteremic episode in the case group, we
identified the earlier and following patient with
community-onset bacteremia, according to the arrival time
in the ED. Two control patients were included for each
study case. Patients with regular renal replacementtherapy, hospital-acquired infections, or incomplete med-
ical record were replaced by the next eligible patient.
The medical records of the included bacteremic epi-
sodes were reviewed. Demographic data, underlying dis-
eases, recent medical intervention, clinical manifestations,
laboratory data within the first 24 hours upon presentation,
microbiology studies, antimicrobial treatment, length of
hospital stays, and clinical outcome were collected. Be-
sides, serum creatinine level before and after the bacter-
emia episode was recorded. The sources of infection were
determined by the investigators based on medical records
and radiological or sonographic images.
Microbiology and antimicrobial susceptibility
Blood cultures were collected by the ED staff in two bottles
and loaded into the BACTEC 9240 system (Becton, Dickinson
and Company, Franklin Lakes, NJ, USA). Subcultures onto
plates with Trypticase soy agar with 5% sheep blood (Bec-
ton, Dickinson and Company), eosinemethylene blue agar
(Levine agar; Becton, Dickinson and Company), chocolate
agar, and CDC anaerobic blood agar (Becton, Dickinson and
Company) were performed when the initial results were
positive. Biochemical tests and the VITEK automatic iden-
tification system (bioMe´rieux, Marcy-l’E´toile, France) were
used for final identification. In vitro antimicrobial suscep-
tibility tests of blood isolates were performed by the disc
diffusion method on Mu¨llereHinton agar. The results were
interpreted according to the Clinical Laboratory Standard
Institute guidelines.8
Definitions
Bacteremia was defined as isolation of bacteria from at
least one set of blood culture bottles; however, the
following bacteria should be isolated from at least two sets
of blood cultures in order to classify the infection as “true
bacteremia”9,10: coagulase-negative staphylococci, aerobic
Gram-positive bacilli, Micrococcus species, Clostridium
perfringens, and Propionibacterium species. Polymicrobial
bacteremia was defined as the isolation of more than one
bacterial species from each bacteremic episode. Effective
antimicrobial therapy was defined as administration of an-
tibiotics to which the pathogen was susceptible in vitro.
The severity of bloodstream infections on presentation
was measured by the Pittsburgh bacteremia score, a vali-
dated scoring system based on fever, hypotension, mental
status, mechanical ventilation, and the presence of cardiac
arrest.11 With regard to the infection types, hospital-
acquired infection was defined according to the World
Table 1 Demographic data and comorbidities of the KTRs
and the patients without kidney transplant (control) having
community-onset bacteremia
Variables Number of patients (%) p
KTR group
(n Z 31)
Control group
(n Z 82)
Age, y (mean  SD) 49.5  9.3 69.4  14.8 <0.001
Age > 65 y 1 (3.2) 45 (56.1) <0.001
Sex: male 13 (41.9) 46 (56.1) 0.441
Comorbidities
Chronic kidney
diseasea
31 (100) 14 (17.1) <0.001
Hypertension 20 (64.5) 35 (42.7) 0.238
Diabetes mellitus 11 (35.5) 25 (30.5) 0.717
Autoimmune
disease
3 (9.7) 2 (2.4) 0.143
Old stroke 2 (6.5) 15 (18.3) 0.236
Congestive heart
failure
1 (3.2) 5 (6.1) >0.99
Malignancy 1 (3.2) 31 (37.8) <0.001
Hepatic cirrhosis 0 (0) 12 (14.6) 0.037
a Chronic kidney disease: definition according to the KDIGO
chronic kidney disease guideline.15.
KDIGO guideline Z The Kidney Disease Improving Global Out-
comes guideline; KTR Z kidney transplant recipients.
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infections included infections occurring in patients who
received the specialized nursing care or intravenous ther-
apy at home, attended a hospital, received intravenous
chemotherapy in the past 30 days, hospitalized for 2 or
more days in the past 90 days, or residents of long-term
care facilities.13
Acute kidney injury (AKI) was defined as a 50% elevation
in serum creatinine level within 7 days or an increase of
0.3 mg/dL within 48 hours. Incomplete resolution of the
kidney injury was defined as no normalization of estimated
glomerular filtration rate (GFR) to the baseline level within
3 months after the bacteremia onset that could not be
attributed to another distinct kidney injury event.14 Taking
the laboratory limitation into consideration, a difference in
serum creatinine level of at least 0.2 mg/dL is required to
detect GFR changes.
Statistical analysis
All statistical analyses were performed using R version 3.0.2
[R core team (2013), R Foundation for Statistical
Computing, Vienna, Austria]. Continuous variables were
presented as means  standard deviations or medians
(1ste3rd quartile) according to the distribution tested by the
ShapiroeWilk test. Student t test or Wilcoxon rank-sum test
was applied for between-group comparison for normally or
non-normally distributed variables, respectively. Category
variables were compared by Pearson’s c2 test or Fisher’s
exact test when appropriate.
Results
Of the 564 KTRs (53.5% male) in the study period, we
identified 40 KTRs with bacteremia. Eight patients on he-
modialysis at the onset of bacteremia and a patient with
hospital-acquired infection were excluded. Therefore, the
KTR group finally included 31 KTRs (with 41 episodes of
community-onset bacteremia). The male-to-female ratio
was 1:1.4. One patient had four bacteremic episodes and
seven experienced two episodes with the minimal interval
of 1 month between bacteremic episodes. Eighty-two pa-
tients without regular hemodialysis having bacteremic ep-
isodes were included as the control group.
The KTR group was younger (49.5  9.3 vs. 64.9  14.8
years, p < 0.001), none had hepatic cirrhosis (0% vs. 14.6%,
pZ 0.037), and only one had malignancies (3.2% vs. 37.8%,
p < 0.001). No significant differences in the presence of
diabetes mellitus, hypertension, or old stroke were
demonstrated in the KTR and control groups (Table 1).15
All KTRs received immunosuppressive agents (Table 2).
In the KTR group, 28 (68.3%) of the 41 episodes developed
>6 months after the kidney transplantation. The proportion
of severe sepsis, indicated by a Pittsburgh bacteremia score
of 4 or more, was similar in the two groups (7.3% vs. 15.9%,
p Z 0.391). In the KTR group, only one patient underwent
recent chemotherapy compared with 12 patients in the
control group (p Z 0.064). The laboratory parameters
associated with sepsis, such as leukocytosis, thrombocyto-
penia, and elevated serum C-reactive protein, were not
different. The KTR group had a higher serum creatininelevel at initial presentation (1.8 mg/dL vs. 1.0 mg/dL,
p < 0.001). Half of the KTR group had a certain degree of
AKI along with the bacteremia episodes, compared with
39.5% in the control group (p Z 0.164).
The KTR group was more likely to have urinary tract
infections (UTIs; 61% vs. 23.2%, p Z 0.004), but intra-
abdominal infections less frequently (9.8% vs. 25.6%,
p Z 0.099), especially biliary tract infections (BTIs; 0% vs.
11%, p Z 0.018). In the KTR group, acute graft pyelone-
phritis with local pain or tenderness was discovered in six
[24%; 4 male patients (16%)] of the 25 UTI episodes in the
KTR group. Polymicrobial bacteremia was detected in one
patient in the KTR group and in 11 patients in the control
group (p Z 0.104).
Gram-negative bacilli are the major causes of bacter-
emia in both groups, accounting for 80.5%% and 65.9% of the
patients in the KTR and control groups, respectively
(p Z 0.492; Table 3). Escherichia coli was the most com-
mon pathogen in both groups and the proportion of ESBL-
producing strain was similar (4.9% vs. 6.1%, p > 0.99).
The control group had more Klebsiella pneumoniae
bacteremia (0% vs. 17.1%, p Z 0.010). With regard to
antimicrobial susceptibility for Enterobacteriaceae isolates
or uropathogens (Table 4), no differences were demon-
strated for cephalosporins, gentamicin, or fluoroquinolones
(either ciprofloxacin, levofloxacin, or lomefloxacin; all
p > 0.6).
Timing of effective antimicrobial therapies and clinical
outcomes are shown in Table 5. The proportion of initiation
of effective therapy within 24 hours was not different be-
tween the two groups (80.5% vs. 69.5%, pZ 0.614). The in-
hospital (2.4% vs. 10%, p Z 0.172) and 1-year (10% vs.
29.6%, p Z 0.061) mortality rate were lower in the KTR
Table 2 Clinical characteristics, disease severity, laboratory data, and bacteremia source among the KTRs and the patients
without kidney transplant (control) having community-onset bacteremia
Variables Number of cases (%) p
KTR group (n Z 41) Control group (n Z 82)
Health-care-associated infection 13 (31.7) 44 (53.7) 0.152
Clinical events within 4 wk before the bacteremia
Recipient of immunosuppressants 41 (100) 2 (2.4) <0.001
Hospitalization 10 (24.4) 24 (29.3) 0.666
Surgery 1 (2.4) 2 (2.4) >0.99
Chemotherapy 1 (2.4) 12 (14.6) 0.064
From symptom onset to ED visit (d) 1 (0e1) 1 (0e2) 0.339
Severity
Hypotension 7 (17.1) 29 (35.4) 0.110
Pitt bacteremia score  4 3 (7.3) 13 (15.9) 0.391
Acute altered consciousness 1 (2.4) 12 (14.6) 0.064
Acute kidney injurya 20/40 (50) 24/79 (30.4) 0.164
Laboratory data
WBC > 9000/mm3 30 (73.2) 54 (65.9) 0.723
Absolute neutrophil count <500/mm3 0 (0) 6 (7.3) 0.176
Platelet < 105/mm3 7 (17.1) 18 (25) 0.604
Serum creatinine (mg/dL) 1.8 (1.5e2.7) 1.0 (0.8e1.5) <0.001
C-reactive protein > 100 mg/La 16 (39.0) 42/81 (51.9) 0.417
Source of bacteremia
Primary bacteremia 6 (14.6) 22 (26.8) 0.220
Urinary tract infection 25 (61.0) 18 (22.0) 0.004
Intra-abdominal infection 4 (9.8) 21 (25.6) 0.099
Biliary tract infection 0 (0) 11 (13.4) 0.018
Liver abscess 0 (0) 3 (3.6) 0.550
Skin and soft-tissue infection 3 (7.3) 5 (6.1) >0.99
Respiratory tract infection 2 (4.9) 11 (13.4) 0.227
Endovascular infection 1 (2.4) 0 (0) 0.339
Deep neck infection 0 (0) 2 (2.4) >0.99
a Missing data in some patients.
ED Z emergency department; KTR Z kidney transplant recipients; WBC Z white blood cell.
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Among the survivors, the length of hospital stay was shorter
in the KTR group (6 days vs. 11 days, p Z 0.020) and the
proportions of incomplete resolution of kidney injury after
AKI events were similar between the two groups (21.1% vs.
25%, p > 0.99).
A further analysis focusing on the patients aged 65
years showed that there were 30 patients with 40 bacter-
emia episodes in the KTR group and 36 patients in the
control group. Patients in the nonelderly KTRs group still
had higher prevalence of hypertension (63.3% vs. 19.4%,
p Z 0.017) and fewer malignancies (3.3% vs. 33.3%,
pZ 0.012) than those in the nonelderly control group. The
in-hospital mortality rate was not statistically different
between the two nonelderly groups (2.5% vs. 5.6%,
pZ 0.606). The length of hospital stay among survivors was
shorter in the nonelderly patients in the KTRs group (6 days
vs. 11 days, p Z 0.018).
Discussion
As described in previous studies, UTIs represent the ma-
jority of bacteremia source among the KTRs.16,17 The high
proportion of urosepsis, accounting for 61% of bacteremiasource compared with 30e48% in previous studies, might be
attributed to the community-onset settings, which limited
the numbers of vascular catheter-related infection mostly
occurring in the hospitals.1,2,6,17 The age and male-to-
female ratio may influence the results, because women
are more likely to experience UTIs and young men have a
lower risk, as compared with older men.18 We observed a
similar condition in the KTR group with the male-to-female
ratio of 1:5.3, which echoed the findings of a previous study
showing an odds ratio of 5.8 for females to develop UTIs
among the KTRs.19 By contrast, patients with urosepsis in
the control group had a male-to-female ratio of 1:0.64 and
a mean age of 64.8 years.
Virtually all urosepsis episodes in the KTR group met the
definition of acute graft pyelonephritis, that is, fever with
one or more of the following clinical symptoms, signs, or
biological abnormalities: painful graft, chills, cystitis,
dysuria, pyuria, bacteriuria, and increased serum creati-
nine level.20,21 However, only 24% of the patients in the KTR
group had local symptoms or signs in the transplanted kid-
neys. Some authors pointed out that the loss of nerve
connection at the transplants might explain this phenom-
enon of infrequent localized tenderness in the
transplants.22
Table 3 Causative pathogens of bacteremia in the KTRs
and the patients without kidney transplant (control)
Variables Number of cases (%) p
KTR group
(n Z 41)
Control
group
(n Z 82)
Gram-negative aerobes 33 (80.5) 54 (65.9) 0.492
Escherichia coli 21 (51.2) 34 (41.5) 0.530
ESBL-producing
E. coli
2 (4.9) 5 (6.10) >0.99
Klebsiella pneumoniae 0 (0) 14 (17.1) 0.010
Salmonella enteritidis 3 (7.3) 2 (2.4) 0.338
Pseudomonas
aeruginosa
2 (4.9) 2 (2.4) 0.604
Proteus mirabilis 2 (4.9) 1 (1.2) 0.268
Enterobacter cloacae 1 (2.4) 2 (2.4) >0.99
Brevundimonas
vesicularis
1 (2.4) 0 (0) 0.339
Moraxella spp. 1 (2.4) 0 (0) 0.339
Aeromonas spp. 0 (0) 2 (2.4) >0.99
Kluyvera spp. 0 (0) 1 (1.2) >0.99
Gram-positive aerobes 6 (14.6) 23 (28.0) 0.185
Staphylococcus species 2 (4.9) 11 (13.4) 0.227
Methicillin-resistant
Staphylococcus aureus
0 (0) 2 (2.4) >0.99
Streptococcus species 4 (9.8) 12 (14.6) 0.582
Enterococcus species 1 (2.4) 3 (3.6) >0.99
Anaerobes 2 (4.8) 8 (9.8) 0.499
Bacteroides species 2 (4.9) 5 (6.1) >0.99
Fusobacterium species 0 (0) 1 (1.2) >0.99
Peptostreptococcus
species
0 (0) 1 (1.2) >0.99
ESBL Z extended-spectrum beta-lactamase; KTR Z kidney
transplant recipient.
Table 5 Antimicrobial therapy and clinical outcome of
the KTRs and the patients without kidney transplant (con-
trol) having community-onset bacteremia
Variablesa Number of cases (%) p
KTR group
(n Z 41)
Control
group
(n Z 82)
Initiation of effective
drugs within 24 h
33 (80.5) 47 (69.5) 0.614
Discharge from the
emergency
department
4 (9.8) 7 (8.5) >0.99
Admission to
intensive
care units
5/37 (13.5) 11/72 (15.3) 0.831
Hospital stay among
survivors, d
6 (3e10) 11 (6e14) 0.020
Mortality
In-hospital 1 (2.4) 10 (12.2) 0.172
At 28 d 1 (2.4) 10/76 (13.2) 0.100
At 12 mo 4/40 (10) 21/71 (29.6) 0.061
a Not all cases had the indicated information.
KTR Z kidney transplant recipient.
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related to less hepatobiliary infections in this group.
Because E. coli is also the major pathogen of intra-
abdominal infections, it is not surprising that a similar
predominance of E. coli bacteremia was shown in both the
KTR and control groups. It is interesting that none of the
bacteremia episodes in the KTR group was attributed toTable 4 Antimicrobial susceptibility of selected drugs for specifi
kidney transplant (control)
Drugs All Enterobacteriaceae
Case number (%)
KTR group
(n Z 29)
Control group
(n Z 55)
Cefazolin 19 (65.5) 39 (70.9)
Cefuroxime 21 (72.4) 43 (78.2)
CTX/CRO 27 (93.1) 48 (87.3)
Fluoroquinolonesa 22 (75.9) 46 (83.6)
Gentamicin 21 (72.4) 42 (76.4)
a Fluoroquinolones: ciprofloxacin, levofloxacin, or lomefloxacin.
CRO Z ceftriaxone; CTX Z Cefotaxime; KTR Z kidney transplant recBTIs. Although prophylactic cholecystectomy has been
recommended in some countries in patients with asymp-
tomatic cholelithiasis before kidney transplantation, the
procedure is not performed in Taiwan.23 The prevalence of
cholelithiasis in the KTRs would be expected to be similar to
that of the general population, and it is possible that the
KTRs will develop BTIs later in their life as those with BTIs in
the control group (mean age was 75 years).24
With regard to the consequences of bacteremia, the KTR
group did not have increased mortality, a longer hospital
stay, or a higher degree of renal function deterioration.
Similar results were obtained upon comparing the non-
elderly patient groups. In addition, the mortality rate in the
KTR group is also numerically lower than that reported in
two previous cohorts, which included nonelderly patients
with community-onset bacteremia. Kollef et al reported a
crude mortality rate of 4.1% in 415 American adults (mean
age, 55 years) with community-acquired bacteremia25, andc bacteremic isolates from the KTRs and the patients without
p Uropathogens p
Case number (%)
KTR group
(n Z 25)
Control group
(n Z 19)
0.827 17 (68) 15 (60) 0.749
0.827 18 (72) 15 (60) 0.843
0.846 24 (96) 15 (60) 0.663
0.778 19 (76) 15 (60) 0.934
0.880 17 (68) 15 (60) 0.749
ipient.
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there was a 30-day mortality rate of 11%.26
Younger age and fewer malignancies in the KTR group
reflected the selection preference for transplantation
candidates, and probably offset the adverse impact of im-
munosuppressants on the outcome of community-onset
septicemia. A lower disease severity at initial presenta-
tion, which reasonably results from the health education
offered by the transplantation team and less intra-
abdominal infections, may be related to a lower hospital
stay. Although the intervals between symptom onset and
presentation did not differ between the two groups, the
fact that a higher proportion (14.6%) of the control group
presented with acute altered mental status would lead to
underestimation of this parameter since these unconscious
patients were sent to the ED immediately and their initial
subjective symptoms were usually inaccessible.
This study had several limitations. A single-center
setting limited its generalization of the study findings.
The retrospective design may introduce classification errors
owing to insufficient information, event documentation, or
selection biases. Moreover, we did not evaluate the pa-
tients with community-onset bacteremia visiting outpatient
clinics or other hospitals and this would underestimate the
case numbers of community-onset bacteremia in the KTRs.
Some differences in baseline characteristics in the two
groups made any causal inference difficult. Further studies
comparing KTRs with other age- and sex-matched controls
are thus necessary. Last, some AKI patients may be unde-
tected in the control group. The more sensitive criterion
(0.3 mg/dL increase of serum creatinine within 48 hours)
requires frequent blood samplings. The result that 50% of
AKI patients in the KTR group and 25% in the control group
fulfilled the aforementioned criterion reflected the fact
that less frequent blood tests were performed for the pa-
tients in the control group.14
In conclusion, the KTRs with community-onset bacter-
emia had comparable clinical severity, antimicrobial sus-
ceptibility, and outcome to the control patients, despite
different distribution of infection sources and pathogens.
Our study indicates that the KTRs with community-onset
bacteremia fare well, if they have access to medical care in
time.
Conflicts of interest
All contributing authors declare no conflicts of interest.
References
1. Silva Jr M, Marra AR, Pereira CA, Medina-Pestana JO,
Camargo LF. Bloodstream infection after kidney trans-
plantation: epidemiology, microbiology, associated risk fac-
tors, and outcome. Transplantation 2010;90:581e7.
2. Moreno A, Cervera C, Gavalda´ J, Rovira M, de la Ca´mara R,
Jarque I, et al. Bloodstream infections among transplant re-
cipients: results of a nationwide surveillance in Spain. Am
J Transplant 2007;7:2579e86.
3. Anderson RJ, Schafer LA, Olin DB, Eickhoff TC. Septicemia in
renal transplant recipients. Arch Surg 1973;106:692e4.
4. Kutinova A, Woodward RS, Ricci JF, Brennan DC. The incidence
and costs of sepsis and pneumonia before and after renaltransplantation in the United States. Am J Transplant 2006;6:
129e39.
5. Vidal E, Torre-Cisneros J, Blanes M, Montejo M, Cervera C,
Aguado JM, et al. Bacterial urinary tract infection after solid
organ transplantation in the RESITRA cohort. Transpl Infect Dis
2012;14:595e603.
6. Wu SW, Liu KS, Lin CK, Hung TW, Tsai HC, Chang HR, et al.
Community-acquired urinary tract infection in kidney trans-
plantation: risk factors for bacteremia and recurrent infection.
J Formos Med Assoc 2013;112:138e43.
7. Lim JH, Cho JH, Lee JH, Park YJ, Jin S, Park GY, et al. Risk
factors for recurrent urinary tract infection in kidney trans-
plant recipients. Transplant Proc 2013;45:1584e9.
8. Clinical and Laboratory Standards Institute. Performance
standards for antimicrobial susceptibility testing: 18th infor-
mational supplement. CLSI document M100-S18. Wayne, PA:
Clinical and Laboratory Standards Institute; 2008.
9. Weinstein MP, Towns ML, Quartey SM, Mirrett S, Reimer LG,
Parmigiani G, et al. The clinical significance of positive blood
cultures in the 1990s: a prospective comprehensive evaluation
of the microbiology, epidemiology, and outcome of bacteremia
and fungemia in adults. Clin Infect Dis 1997;24:584e602.
10. Lee CC, Lin WJ, Shih HI, Wu CJ, Chen PL, Lee HC, et al. Clinical
significance of potential contaminants in blood cultures among
patients in a medical center. J Microbiol Immunol Infect 2007;
40:438e44.
11. Chow JW, Yu VL. Combination antibiotic therapy versus mon-
otherapy for Gram-negative bacteraemia: a commentary. Int
J Antimicrob Agents 1999;11:7e12.
12. Ducel G, Fabry J, Nicolle L. Prevention of hospital-acquired
infections: a practical guide. 2nd ed. Geneva, Switzerland:
World Health Organization; 2002.
13. Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL,
Briggs JP, et al. Health care-associated bloodstream infections
in adults: a reason to change the accepted definition of
community-acquired infections. Ann Intern Med 2002;137:
791e7.
14. The Kidney Disease Improving Global Outcomes (KDIGO) Acute
Kidney Injury Work Group. KDIGO clinical practice guideline for
acute kidney injury. Kidney Int Suppl 2012;2:1e138.
15. The Kidney Disease Improving Global Outcomes (KDIGO) CKD
Work Group. KDIGO 2012 clinical practice guideline for the
evaluation and management of chronic kidney disease. Kidney
Int Suppl 2013;3:1e150.
16. Wagener MM, Yu VL. Bacteremia in transplant recipients: a
prospective study of demographics, etiologic agents, risk fac-
tors, and outcomes. Am J Infect Control 1992;20:239e47.
17. Rojas L, Mun˜oz P, Kestler M, Arroyo D, Guembe M, Rodrı´guez-
Cre´ixems M, et al. Bloodstream infections in patients with
kidney disease: risk factors for poor outcome and mortality.
J Hosp Infect 2013;85:196e205.
18. Lipsky BA. Urinary tract infections in men. Epidemiology,
pathophysiology, diagnosis, and treatment. Ann Intern Med
1989;110:138e50.
19. Chuang P, Parikh CR, Langone A. Urinary tract infections after
renal transplantation: a retrospective review at two US trans-
plant centers. Clin Transplant 2005;19:230e5.
20. Kamath NS, John GT, Neelakantan N, Kirubakaran MG,
Jacob CK. Acute graft pyelonephritis following renal trans-
plantation. Transpl Infect Dis 2006;8:140e7.
21. Giral M, Pascuariello G, Karam G, Hourmant M, Cantarovich D,
Dantal J, et al. Acute graft pyelonephritis and long-term kid-
ney allograft outcome. Kidney Int 2002;61:1880e6.
22. Schmaldienst S, Dittrich E, Ho¨rl WH. Urinary tract infections
after renal transplantation. Curr Opin Urol 2002;12:125e30.
23. Sarkio S, Salmela K, Kyllo¨nen L, Rosliakova M, Honkanen E,
Halme L. Complications of gallstone disease in kidney trans-
plantation patients. Nephrol Dial Transplant 2007;22:886e90.
Bacteremia in kidney transplant recipients 69124. Greenstein SM, Katz S, Sun S, Glicklich D, Schechner R,
Kutcher R, et al. Prevalence of asymptomatic cholelithiasis and
risk of acute cholecystitis after kidney transplantation.
Transplantation 1997;63:1030e2.
25. Kollef MH, Zilberberg MD, Shorr AF, Vo L, Schein J, Micek ST,
et al. Epidemiology, microbiology and outcomes of healthcare-associated and community-acquired bacteremia: a multicenter
cohort study. J Infect 2011;62:130e5.
26. Søgaard M, Schønheyder HC, Riis A, Sørensen HT, Nørgaard M.
Short-termmortality in relation to age and comorbidity in older
adults with community-acquired bacteremia: a population-
based cohort study. J Am Geriatr Soc 2008;56:1593e600.
